Tau Platelets Correlate with Regional Brain Atrophy in Patients with Alzheimer's Disease.
暂无分享,去创建一个
J. Becker | O. Lopez | A. Slachevsky | P. Reyes | E. Bravo | R. Maccioni | C. Muñoz-Neira | C. Delgado | G. Farías | L. Guzmán-Martínez | C. Garrido | M. Farías | P. Flores
[1] R. Kalaria,et al. Platelet Tau Protein as a Potential Peripheral Biomarker in Alzheimer's Disease: An Explorative Study. , 2018, Current Alzheimer research.
[2] Xintao Hu,et al. Network-selective vulnerability of the human cerebellum to Alzheimer's disease and frontotemporal dementia. , 2016, Brain : a journal of neurology.
[3] Jorge Sepulcre,et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.
[4] Ya-Fang Chen,et al. Plasma tau as a window to the brain—negative associations with brain volume and memory function in mild cognitive impairment and early alzheimer's disease , 2014, Human brain mapping.
[5] D. Ryglewicz,et al. Correlations between cerebellar and brain volumes, cognitive impairments, ApoE levels, and APOE genotypes in patients with AD and MCI. , 2013, Current Alzheimer research.
[6] Frederik Barkhof,et al. Different patterns of gray matter atrophy in early- and late-onset Alzheimer’s disease , 2013, Neurobiology of Aging.
[7] Henrik Zetterberg,et al. Plasma tau levels in Alzheimer's disease , 2013, Alzheimer's Research & Therapy.
[8] Andrea Slachevsky Ch,et al. [Psychometric properties and diagnostic usefulness of the Addenbrooke's Cognitive Examination-Revised in a Chilean elderly sample]. , 2012, Revista medica de Chile.
[9] Olivier Colliot,et al. CSF tau markers are correlated with hippocampal volume in Alzheimer's disease , 2012, Neurobiology of Aging.
[10] J. Schneider,et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.
[11] Dominic Holland,et al. Amyloid‐β associated volume loss occurs only in the presence of phospho‐tau , 2011, Annals of neurology.
[12] H. Soininen,et al. Plasma Aβ42 and Aβ40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study , 2010, Journal of Neurology, Neurosurgery & Psychiatry.
[13] Nick C Fox,et al. The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.
[14] Ulrich Seidl,et al. The cerebellum in mild cognitive impairment and Alzheimer's disease - a structural MRI study. , 2008, Journal of psychiatric research.
[15] K. Ashe,et al. Accumulation of Pathological Tau Species and Memory Loss in a Conditional Model of Tauopathy , 2007, The Journal of Neuroscience.
[16] A. Hofman,et al. Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study , 2006, The Lancet Neurology.
[17] S. Maeda,et al. Increased levels of granular tau oligomers: An early sign of brain aging and Alzheimer's disease , 2006, Neuroscience Research.
[18] R. Maccioni,et al. Anomalously phosphorylated tau and Aβ fragments in the CSF correlates with cognitive impairment in MCI subjects , 2006, Neurobiology of Aging.
[19] F. Rothhammer,et al. ApoE alleles and tau markers in patients with different levels of cognitive impairment. , 2005, Archives of medical research.
[20] J. Cummings,et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.
[21] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[22] J. Morrison,et al. Progressive degeneration of nonphosphorylated neurofilament protein‐enriched pyramidal neurons predicts cognitive impairment in Alzheimer's disease: Stereologic analysis of prefrontal cortex area 9 , 2003, The Journal of comparative neurology.
[23] H. Braak,et al. Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.
[24] Karl J. Friston,et al. A Voxel-Based Morphometric Study of Ageing in 465 Normal Adult Human Brains , 2001, NeuroImage.
[25] I Litvan,et al. The FAB: A frontal assessment battery at bedside , 2000, Neurology.
[26] K Ball,et al. Visual attention impairments in Alzheimer’s disease , 2000, Neurology.
[27] H. Wiśniewski,et al. Plasma amyloid β‐peptide 1–42 and incipient Alzheimer's disease , 1999 .
[28] K. Davis,et al. Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. , 1999, Archives of neurology.
[29] C. Jack,et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment , 1999, Neurology.
[30] A. Toga,et al. Cortical variability and asymmetry in normal aging and Alzheimer's disease. , 1998, Cerebral cortex.
[31] J. Kaye,et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.
[32] J. Nunez,et al. Diversity of High‐Molecular‐Weight τ Proteins in Different Regions of the Nervous System , 1994, Journal of neurochemistry.
[33] J. Nunez,et al. High and Low Molecular Weight r Proteins Are Differentially Expressed from a Single Gene , 1993, Journal of neurochemistry.
[34] R. Liem,et al. Expression of high molecular weight tau in the central and peripheral nervous systems. , 1993, Journal of cell science.
[35] R. Liem,et al. Primary structure of high molecular weight tau present in the peripheral nervous system. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[36] D. Grossi,et al. Mamillary bodies in Alzheimer's disease , 1989, Acta neurologica Scandinavica.
[37] M. Kirschner,et al. Regulation of microtubule protein levels during cellular morphogenesis in nerve growth factor-treated PC12 cells , 1988, The Journal of cell biology.
[38] H. Buschke,et al. Impaired ranking of semantic attributes in dementia , 1985, Brain and Language.
[39] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[40] C. P. Hughes,et al. A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.
[41] H. Nelson. A Modified Card Sorting Test Sensitive to Frontal Lobe Defects , 1976, Cortex.
[42] S. Folstein,et al. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .
[43] R. Reitan. Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .
[44] D. Lahiri. Editorial [Progress of “Current Alzheimer Research” and Future Direction] , 2013 .
[45] A. Slachevsky,et al. Supplementary Material for: The Technology – Activities of Daily Living Questionnaire: A Version with a Technology-Related Subscale , 2012 .
[46] A. Slachevsky,et al. Platelet tau pattern correlates with cognitive status in Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.
[47] A. Slachevsky,et al. Human platelets tau: a potential peripheral marker for Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.
[48] . Global prevalence of dementia: a Delphi consensus study , 2006 .
[49] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[50] Karl J. Friston,et al. COMMENTS AND CONTROVERSIES Why Voxel-Based Morphometry Should Be Used , 2001 .
[51] S A Small,et al. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. , 1999, Annals of neurology.
[52] M. Schlossberg. The Assessment of Aphasia and Related Disorders. 2nd ed. , 1984 .
[53] A. Rey. L'examen psychologique dans les cas d'encéphalopathie traumatique. (Les problems.). , 1941 .